Drug Profile
Research programme: mast cell activation inhibitors - AstraZeneca
Alternative Names: Mast cell activation inhibitors research programme - AstraZenecaLatest Information Update: 09 Dec 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Mast cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 09 Dec 1999 Discontinued-Preclinical for Allergic rhinitis in Sweden (PO)
- 09 Dec 1999 Discontinued-Preclinical for Asthma in Sweden (PO)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed